Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Michael P Bogenschutz, Samantha K Podrebarac, Jessie H Duane, Sean S Amegadzie, Tara C Malone, Lindsey T Owens, Stephen Ross, Sarah E Mennenga, Michael P Bogenschutz, Samantha K Podrebarac, Jessie H Duane, Sean S Amegadzie, Tara C Malone, Lindsey T Owens, Stephen Ross, Sarah E Mennenga

Abstract

After a hiatus of some 40 years, clinical research has resumed on the use of classic hallucinogens to treat addiction. Following completion of a small open-label feasibility study, we are currently conducting a double-blind placebo-controlled clinical trial of psilocybin-assisted treatment of alcohol use disorder. Although treatment effects cannot be analyzed until the study is complete, descriptive case studies provide a useful window into the therapeutic process of psychedelic-assisted treatment of addiction. Here we describe treatment trajectories of three participants in the ongoing trial to illustrate the range of experiences and persisting effects of psilocybin treatment. Although it is difficult to generalize from a few cases, several qualitative conclusions can be drawn from the data presented here. Although participants often find it difficult to describe much of their psilocybin experience, pivotal moments tend to be individualized, extremely vivid, and memorable. Often, the qualitative content extends beyond the clinical problem that is being addressed. The participants discussed in this paper experienced acute and lasting alterations in their perceptions of self, in the quality of their baseline consciousness, and in their relationship with alcohol and drinking. In these cases, experiences of catharsis, forgiveness, self-compassion, and love were at least as salient as classic mystical content. Finally, feelings of increased "spaciousness" or mindfulness, and increased control over choices and behavior were reported following the drug administration sessions. Ultimately, psilocybin-assisted treatment appears to elicit experiences that are extremely variable, yet seem to meet the particular needs of the individual.

Keywords: addiction; alcohol use disorder; hallucinogen; psilocybin; psychedelics.

Figures

FIGURE 1
FIGURE 1
Quantitative data from the three cases presented. Percent drinking days, percent heavy drinking days, and average number of drinks per drinking day are shown for each participant throughout the study. Scores on the Penn Alcohol Craving, Short Inventory of Problems, Self-Efficacy, Hamilton Anxiety, Hamilton Depression, and Self-compassion scales are presented throughout the study.

References

    1. Barrett F. S., Johnson M. W., Griffiths R. R. (2015). Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J. Psychopharmacol. 29 1182–1190. 10.1177/0269881115609019
    1. Belser A. B., Agin-Liebes G., Swift T. C., Terrana S., Devenot N., Friedman H. L., et al. (2017). Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis. J. Humanist. Psychol. 57 354–388. 10.1177/0022167817706884
    1. Bogenschutz M. P., Forcehimes A. A. (2016). Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism. J. Humanist. Psychol. 57 1–26.
    1. Bogenschutz M. P., Forcehimes A. A., Pommy J. A., Wilcox C. E., Barbosa P. C., Strassman R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J. Psychopharmacol. 29 289–299. 10.1177/0269881114565144
    1. Carhart-Harris R. L., Bolstridge M., Rucker J., Day C. M., Erritzoe D., Kaelen M., et al. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3 619–627. 10.1016/S2215-0366(16)30065-7
    1. Griffiths R. R., Johnson M. W., Carducci M. A., Umbricht A., Richards W. A., Richards B. D., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30 1181–1197. 10.1177/0269881116675513
    1. Grof S., Goodman L. E., Richards W. A., Kurland A. A. (1973). LSD-assisted psychotherapy in patients with terminal cancer. Int. Pharmacopsychiatry 8 129–144. 10.1159/000467984
    1. Hoffer A. (1967). “A program for treatment of alcoholism: LSD, malvaria, and nicotinic acid,” in The Use of LSD in Psychotherapy and Alcoholism ed. Abramson H. A. (Indianapolis, IN: Bobbs-Merrill; ) 343–406.
    1. Hollister L. E., Shelton J., Krieger G. (1969). A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am. J. Psychiatry 125 1352–1357. 10.1176/ajp.125.10.1352
    1. Johnson M. W., Garcia-Romeu A., Cosimano M. P., Griffiths R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J. Psychopharmacol. 28 983–992. 10.1177/0269881114548296
    1. Krebs T. S., Johansen P. O. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J. Psychopharmacol. 26 994–1002. 10.1177/0269881112439253
    1. MacLean K. A., Leoutsakos J.-M., Johnson M. W., Griffiths R. R. (2012). Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J. Sci. Study Relig. 51 721–737. 10.1111/j.1468-5906.2012.01685.x
    1. Pahnke W. N. (1963). Drugs and Mysticism: An Analysis of the Relationship between Psychedelic Drugs and the Mystical Consciousness. Doctoral Dissertion, Harvard University, Cambridge, MA.
    1. Pahnke W. N., Kurland A. A., Unger S., Savage C., Grof S. (1970). The experimental use of psychedelic (LSD) psychotherapy. JAMA 212 1856–1863. 10.1001/jama.1970.03170240060010
    1. Ross S., Bossis A., Guss J., Agin-Liebes G., Malone T., Cohen B., et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30 1165–1180. 10.1177/0269881116675512
    1. Sherwood J. N., Stolaroff M. J., Harman W. W. (1962). The psychedelic experience–a new concept in psychotherapy. J. Neuropsychiatry 4 69–80.
    1. Stace W. T. (1960). Mysticism and Philosophy. New York, NY: St. Martin’s Press.
    1. Swift T. C., Belser A. B., Agin-Liebes G., Devenot N., Terrana S., Friedman H. L., et al. (2017). Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J. Humanist. Psychol. 57 488–519. 10.1177/0022167817715966

Source: PubMed

3
Předplatit